ATHE: Alterity Therapeutics Ltd. EV/EBITDA Multiple
Alterity Therapeutics (ATHE) is developing innovative treatments for parkinsonism, leveraging an intellectual monopoly and low production costs. The market dynamics of the securities based on the EV/EBITDA metric stand at 0.00. The company attracts leading scientists through a lack of bureaucracy and stock options; however, the business's financial stability depends heavily on the trial outcomes of its sole pipeline of drugs for treating rare brain pathologies.
Analytical breakdowns for alteritytherapeutics.com (ATHE)
- stock price and consensus target price:
- market capitalization information:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Equity Ratio Alterity Therapeutics|ATHE - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Alterity Therapeutics Limited|ATHE - Company Cumulative Debt|Debt to Book Value Alterity Therapeutics Limited|ATHE - Company Long-Term Loans and Borrowings|Company Current Liabilities Alterity Therapeutics|Quick Ratio alteritytherapeutics.com
- business earnings and investment ratios data:
ATHE - Final Profit|Projected Future Earnings Alterity Therapeutics|ATHE - Market Cap to Earnings|Future Price to Earnings Alterity Therapeutics Limited|ATHE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Alterity Therapeutics Limited|ATHE - Operating profit EBITDA|Earnings per share for the last twelve months Alterity Therapeutics|ATHE - Earnings per one share for the last 12 months|Quarterly EPS earnings growth alteritytherapeutics.com|ATHE - Earnings per share growth rate in current year|Expected earnings per share growth for next year Alterity Therapeutics
- company sales and revenue statistics:
Initial company analysis:Alterity Therapeutics Ltd (ATHE)
Institutional capital evaluates Alterity Therapeutics (ATHE) through the lens of the business's ability to cover the total cost of assets and debts via operating profit. By analyzing the Enterprise Value to EBITDA trend, investors determine the company's resilience to financial stress until insurance payments for Parkinson's disease therapy are received, allowing them to differentiate the asset's real value from speculative expectations.
Key competitors
Biogen Corp - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio NBIX (Neurocrine Corp)|Regencell Bioscience - EV/EBITDA Multiple|Company Value to EBITDA axsome.com|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|VKTX (Viking Pharma) - EV/EBITDA Multiple|Supernus Corp (SUPN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Biohaven Ltd (BHVN) - Company Value to EBITDA|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|AVXL: Enterprise Value to Operating Income Before Depreciation Ratio|CBLL (CeriBell) - EV/EBITDA Multiple|PRTA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALEC|ANNX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|VYGR - EV/EBITDA Multiple|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Alpha Cognition Corp ACOG|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|EV/EBITDA Multiple Inhibikase Therapeutics Inc (IKT)|Cassava - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ASRT (Assertio Holdings)|Coya - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vistagen Therapeutics VTGN|OVID: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Acumen Pharmaceuticals Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Clene Nanomedicine (CLNN) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PEPG|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Relmada Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ANVS (Annovis Bio Inc)|Grace Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation AIFF (Firefly Neuro)|KLTO: EV/EBITDA Multiple|Company Value to EBITDA NeuroSense Therapeutics Ltd. (NRSN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Reviva Pharmaceuticals Holdings, Inc.|Enterprise Value to Operating Income Before Depreciation MTVA (MetaVia, Inc.)|EV/EBITDA Multiple NRXS|HSDT - Company Value to EBITDA|Passage Bio - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Neuphoria Therapeutics, Inc. NEUP|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Alzamend Neuro (ALZN)|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Protagenic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CRGT (cortigent.com)|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio BCLI (BrainStorm Cell Therapeutics Inc.)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Company Value to EBITDA chromocell.com|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Intra-Cellular Therapies, Inc. - Business Value to Operating Income Before Depreciation|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Marinus Pharma (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio NRBO|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|TRVN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|CERE: Enterprise Value to Operating Income Before Depreciation Ratio
